抑制糖解促进了对三阴性乳腺癌的检查点阻塞疗法
Chong Li1, Yu Tang2, Ruizhi Zhang1
1Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Discover oncology
|April 17, 2025
概括
在癌症代谢中准Hexokinase 2 (HK2) 可能会增强抗瘤免疫力. 抑制HK2降低了抑制细胞,促进T细胞反应,并在三阴性乳腺癌模型中提高了生存率.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 免疫治疗是一种免疫疗法.
背景情况:
- 癌细胞表现出能量代谢的改变,特别是有氧糖解 (Warburg效应).
- 基酶2 (HK2) 是华堡效应中的一个关键酶,对癌细胞增殖至关重要.
- 准HK2显示了癌症治疗的潜力,副作用最小.
研究的目的:
- 研究HK2在三阴性乳腺癌 (TNBC) 中瘤免疫反应中的作用.
- 评估单独和与免疫疗法结合的HK2抑制对TNBC的治疗潜力.
主要方法:
- 利用4T1细胞系和三阴性乳腺癌的小鼠模型.
- 使用HK2抑制剂 (3-BrPA) 和抗PD-L1治疗.
- 评估了G-CSF表达,髓质衍生抑制细胞 (MDSC) 发育,T细胞免疫力和整体存活率.
主要成果:
- 在4T1细胞中,HK2抑制降低了G-CSF表达和MDSC发育.
- 这导致增强的T细胞免疫力,并延长了瘤携带小鼠的存活时间.
- 在TNBC小鼠模型中,HK2抑制剂3-BrPA提高了抗PD-L1治疗的疗效.
结论:
- 在TNBC中,HK2在调节瘤免疫微环境方面发挥着重要作用.
- 通过HK2抑制准糖解是一种增强抗瘤免疫力的有希望的策略.
- 将HK2抑制与免疫疗法结合起来,为三阴性乳腺癌提供了一种新的治疗方法.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.5K
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.2K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:27Tumor Immunotherapy
400
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
400
02:38Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
01:15Drugs that Stabilize Microtubules
1.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
1.9K
01:22PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K